Novo Nordisk buys treatment candidate for rare disease for up to USD 1.2bn
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13125622.ece/ALTERNATES/schema-16_9/doc7gme04btwap15ejg0bw7.jpg)
Novo Nordisk has taken over Prothena's drug candidate PRX004, which is being developed to treat ATTR amyloidosis. In the same deal, Novo Nordisk is taking over Prothena's entire wide-ranging ATTR amyloidosis program.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.